Lifeboat Foundation

More cool designs are on Amazon: https://amzn.to/3wDGy2i.
Alternatively, PayPal donations can be sent here: http://paypal.me/whatdamath.

Hello and welcome! My name is Anton and in this video, we will talk about bizarre quantum effects discovered in the last few months.
Links:
https://news.uchicago.edu/story/uchicago-scientists-observe-…laboratory.
https://www.nature.com/articles/s41567-023-02139-8
https://www.nature.com/articles/s41586-023-05727-z.
https://www.nature.com/articles/s42005-022-00881-8
#quantum #quantumphysics #quantummechanics.

0:00 Evidence for quantum superchemistry.
3:40 Solar fusion is quantum and not classical.
5:20 Quantum tunneling and microscopy.
7:00 Tunneling causes chemistry.
7:40 Tunneling affects DNA and causes mutation.

Continue reading “Get a Wonderful Person Tee” »

Life runs on ribosomes. Every cell across the globe requires ribosomes to convert genetic data into the vital proteins required for the organism’s operation, and, subsequently, for the production of more ribosomes. However, scientists still lack a clear understanding of how these essential nanomachines are assembled.

Now, new high-resolution images of the large ribosomal subunit are shedding light on how arguably nature’s most fundamental molecule coalesces in human cells. The findings, published in Science, bring us one step closer to a complete picture of ribosome assembly.

“We now have a pretty good idea of how the large ribosomal subunit is assembled in humans,” says Rockefeller’s Sebastian Klinge. “We still have quite a few gaps in our understanding, but we certainly now have a much better idea than we had before.”

Over the past few decades, material scientists and chemists have been working on designing increasingly sophisticated materials for a wide range of technological and scientific applications. These materials include synthetic polymers and hydrogels that could be introduced inside the human body as part of medical interventions.

Researchers at the Leibniz Institute of Polymer Research Dresden, Technische Universität Dresden and other institutes in Germany recently designed new fully synthetic materials with a dynamic DNA-crosslinked matrix that could prove useful for the creation of organoids (artificial organs) and other bio-mimetic systems. These materials, introduced in Nature Nanotechnology, are versatile, programmable and relatively inexpensive, making them advantageous for medical and biological research.

“Polymer chemistry can create materials with wonderful properties,” Elisha Krieg, one of the researchers who carried out the study, told Phys.org. “Think of everyday products like toys and packaging, but also bullet-proof vests, parachutes, medical implants, etc. But these materials are very static—it is not easy to change their properties, once broken they cannot heal themselves, and their characteristics are difficult to predict. Our group tries to make materials that are more akin to living matter: adaptive, self-healing, and programmed to fulfill specific functions.”

Learn about Regeneron’s Spectacular Science and home-grown technologies accelerating drug discovery and development such as VelociGene®, VelociMouse®, VelocImmune® and more.

Scientists at St. Anna Children’s Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children. Crucially, stem cells from a parent provide children with a new immune system that responds much better to immunotherapies. These results of an early clinical trial were published in the prestigious Journal of Clinical Oncology.

Childhood tumors of the nervous system, known as neuroblastomas, are associated with an unfavorable prognosis if the tumor is classified as a high-risk type. The chances are particularly poor for patients in the relapsed stage. In this case, immunotherapy following stem cell transplantation is now associated with long-term survival in a substantial proportion of the patients included in a recent study. Compared to an earlier study the survival rate was increased.

“After the transplantation of stem cells from a parent, the patients are equipped with a new immune system. This enables a better immune response to the subsequent immunotherapy and clearly improves the outcome,” explains Prof. Ruth Ladenstein, MD, head of the Studies & Statistics group for Integrated Research and Projects (S²IRP) at St. Anna Children’s Cancer Research Institute and professor at the Department of Pediatrics and Adolescent Medicine at MedUni Vienna, who played a key role as co-first author.

What happens in femtoseconds in nature can now be observed in milliseconds in the lab.

Scientists at the university of sydney.

The University of Sydney is a public research university located in Sydney, New South Wales, Australia. Founded in 1,850, it is the oldest university in Australia and is consistently ranked among the top universities in the world. The University of Sydney has a strong focus on research and offers a wide range of undergraduate and postgraduate programs across a variety of disciplines, including arts, business, engineering, law, medicine, and science.

A biological pathway through which myelin, the protective coating on nerve fibers, can be repaired and regenerated has been discovered in a new study. The ramifications of this finding could be far-reaching for those with neurological diseases affecting myelin, many of which are currently untreatable.

If the axons that shoot out from the cell bodies of neurons are like electrical wires, you can think of the myelin sheath as the insulating plastic outer coating. In the brain, these sheathed nerve fibers make up most of the tissue known as white matter, but axons throughout the body are also coated in myelin.

The myelin sheath’s main functions are to protect the axon, to ensure electrical nerve impulses can travel quickly down it, and to maintain the strength of these impulses as they travel over what can be very long distances.

Researchers at the Hong Kong University of Science and Technology (HKUST) have found how stem cells’ surrounding environment controls them to differentiate into functional cells, a breakthrough critical for using stem cells to treat various human diseases in the future.

Stem cells play a crucial role in supporting normal development and maintaining tissue homeostasis in adults. Their unique ability to replicate and differentiate into specialized cells holds great promise in treating diseases like Parkinson’s disease, Alzheimer’s disease and type I diabetes by replacing damaged or diseased cells with healthy ones.

Despite their potential therapeutic benefits, one of the major challenges for cell therapies lies in efficiently differentiating stem cells into functional cells to replace damaged cells in degenerative tissue. This task is particularly difficult due to the limited understanding of the underlying molecular mechanism by which the tissues around stem cells, known as the stem cell niche, guide stem cell progeny to differentiate into proper functional cell types.

Cell therapy company BlueRock Therapeutics has revealed promising results from the Phase 1 clinical trial of bemdaneprocel, an investigational stem cell therapy designed to treat Parkinson’s disease. BlueRock, a wholly owned independently operated subsidiary of pharma giant Bayer, is creating a pipeline of cell therapy treatments for neurological, cardiovascular, immunological, and ophthalmic conditions.

Bemdaneprocel is a stem cell therapy developed to replace dopamine-producing neurons that are lost in Parkinson’s disease. Derived from pluripotent stem cells, the therapy involves implanting neuron precursors into the brains of patients to potentially restore neural networks and improve motor and non-motor functions.

“The need for new therapies to help patients struggling with Parkinson’s disease is clear,” said Ahmed Enayetallah, Head of Development at BlueRock Therapeutics. “We are excited to be sharing the results of this Phase 1 and look forward to advancing bemdaneprocel to the next stage of clinical testing.”